Q4 2023 13F Holders as of 12/31/2023
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
78.2M
-
Number of holders
-
11
-
Total 13F shares, excl. options
-
235K
-
Shares change
-
-195K
-
Total reported value, excl. options
-
$299K
-
Value change
-
-$271K
-
Number of buys
-
5
-
Number of sells
-
-7
-
Price
-
$1.27
Significant Holders of Inhibikase Therapeutics, Inc. - Common Stock, $0.001 par value (IKT) as of Q4 2023
15 filings reported holding IKT - Inhibikase Therapeutics, Inc. - Common Stock, $0.001 par value as of Q4 2023.
Inhibikase Therapeutics, Inc. - Common Stock, $0.001 par value (IKT) has 11 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 235K shares
of 78.2M outstanding shares and own 0.3% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (82K shares), BLAIR WILLIAM & CO/IL (60.3K shares), GEODE CAPITAL MANAGEMENT, LLC (28.7K shares), RENAISSANCE TECHNOLOGIES LLC (24.4K shares), Redmond Asset Management, LLC (19.6K shares), STATE STREET CORP (10.1K shares), Tower Research Capital LLC (TRC) (5.92K shares), ROYAL BANK OF CANADA (2K shares), MORGAN STANLEY (1.67K shares), and WELLS FARGO & COMPANY/MN (201 shares).
This table shows the top 11 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.